New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAdamax vs Cartalax

Adamax vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Adamax
Anti-Aging & Longevity
Cartalax
Summary
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
Estimated 1-3 hours (short; peptide degradation)
Short (minutes); gene-regulatory effects are sustained
Admin Route
Subcutaneous, Intranasal (research)
SubQ, Oral
Research
Typical Dose
200-400 mcg per dose
10 mg per day
Frequency
Once daily or every other day
Daily for 10–30 days
Key Benefits
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With